EPROZAR
Brand:
EPROZAR
Manufacturer:
INTAS
Manufacturer Details
INTAS
Compositions:
Eprosartan mesilate 300mg/600mg tablets,
|
Strength
|
Rate
|
Packing Style
|
|
300mg
|
190.00
|
10s tablets
|
|
600mg
|
283.00
|
10s tablets
|
List of Related Indications:
List Of Drugs:
- Eprosartan mesylate - @ Angiotensin II Antagonists(Oct 2008)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Angiotensin II Receptor Antagonists-
Candesartan, Eprosartan, Irbestan, Losartan metabolite, Olmesartran, Telmistran, Valsartan
Prior treatment with diuretcs invcreases risk of excessive hypotension, use a lower dose
Potassium, potassium -sparing diuretics , cyclosporin may increase risk of hypkerkalemia
Monitor potassium
NASIDs including COX-2 inhibitors may reduce antihypertensive response, risk of hyperkalemia or acute failure
Excretion of lithium may be reduced, monitor lithium concentration
Indication:
U.S FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08
Drug name Indication Date of Approval
223. Eporsartan mesylate 400mg/600mg tablets 11-10-08
For the treatment of essential hypertension
Hypertension
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Eprosartan Cardiovascular Merck 09-02-2010
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Eprostatan Mesylate 11-10-2008
400mg/600mg tablets
For the treatment of essential hypertension
Angiotensin II Receptor Antagonists-
Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesatran, Telmistran, Valsartan
Adverse Reaction:
Angiotensin II Receptor Antagonists-
Candesartan, Eprosartan, Irbestan, Losartan metabolite, Olmesatran, Telmistran, Valsartan
=================================================================
EPROSARTAN-
CNS- Dizziness >1% ,Insomnia, Headache < 1%,Fatigue 2%, Anxiety/nervousness < 1% Depression 1%
GI - Diarrhea > 1%, Dyspepsia/heartburn >1%, Nausea/vomiting <1% Abdominal pain 2%
Musculoskeletal- Arthalgia 2% Pain >1% Myalgia >1%
Respiratory - Upper Res tract infn 8% Cough 4% Sinusitis > 1% Pharyngitis 4 %Rhinitis 4%
Influnz like symptoms <1% bronchitis >1%
Miscellaneous - Viral infection 2% Edema > 1% Chest pain >1% Rash <1% tachycardia < 1%
Urinary tract inftn 4% Albuminura ,1% Hyperglyceridemia 1%
Creatinine phosphokinase increased , 1% Hyperglycemia , 1%
Hematuria < 1% Inflicted injury 2%
Contra-Indications:
When used in pregnancy during the second and third trimester, drugs that act directly on the
renin- angiotensin system can cause injury and even death to the developing fetus.
When prergnancy is detected eprosartan mesylate tablets should be discontinued as soon as
possible
Dosages/ Overdosage Etc:
Hypertension
Usual recommended dose- 600mg once daily when used as monotherapy
Can be asministered once or twice daily with total dosage ranging from 400mg to 800mg
Limited experience with dosage beyond 800mg
Patient Information:
Contra-indicated for use during second and third trimester of pregnancy.
Can cause injury and even death to the developing fetus.
Use of eprosartan mesylate tablets should be discontinued during pregnancy
Pharmacology/ Pharmacokinetics:
=================================================================
Angiotensin II Receptor Antagonists-
Candesartan, Eprosartan, Irbestan, Losartan metabolite, Olmesatran, Telmistran, Valsartan
================================================================
Pregnancy and lactation:
Contra-indicated for use during second and third trimester of pregnancy.
Can cause injury and even death to the developing fetus.
When prergnancy is detected eprosartan mesylate tablets should be discontinued as soon as
possible
